The Manufacturers Life Insurance Company lifted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 101.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,720 shares of the company's stock after purchasing an additional 24,988 shares during the period. The Manufacturers Life Insurance Company owned about 0.06% of Viridian Therapeutics worth $953,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Barclays PLC increased its position in Viridian Therapeutics by 113.1% during the third quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after purchasing an additional 66,550 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Viridian Therapeutics by 6.8% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 210,899 shares of the company's stock valued at $4,043,000 after purchasing an additional 13,498 shares during the period. SG Americas Securities LLC lifted its holdings in Viridian Therapeutics by 89.1% in the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after buying an additional 14,644 shares in the last quarter. Moody Aldrich Partners LLC acquired a new position in Viridian Therapeutics in the 4th quarter worth $1,125,000. Finally, R Squared Ltd acquired a new position in Viridian Therapeutics in the 4th quarter worth $26,000.
Analyst Ratings Changes
Several analysts have weighed in on the stock. JMP Securities lowered their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada dropped their price target on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC decreased their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, Viridian Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $36.70.
Read Our Latest Research Report on VRDN
Viridian Therapeutics Stock Up 4.8%
Shares of NASDAQ:VRDN traded up $0.62 during midday trading on Tuesday, hitting $13.44. 109,343 shares of the stock were exchanged, compared to its average volume of 1,189,077. The company has a market capitalization of $1.10 billion, a PE ratio of -3.10 and a beta of 0.57. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The business's fifty day simple moving average is $13.33 and its two-hundred day simple moving average is $17.04.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Viridian Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year. As a group, research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.
About Viridian Therapeutics
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Stories
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
